BIAL Italy granted ISO 9001 certification, an entitlement on Quality Management Systems
BIAL Italy S.R.L has just been successfully granted the ISO 9001:2015 certification, by Certiquality/ IQNET. ISO 9001 takes over a process-based approach, which incorporates the PDCA (Plan-Do-Check-Act) cycle of continuous improvement, and integrates risk-based thinking. With this achievement BIAL Italy demonstrates its trustfulness and quality, with the ability to consistently provide products and services that meet customer, partners and regulatory requirements, using a global recognized standard. In Portugal, BIAL is certified by APCER/ IQNET since 1998. Certificato IQnet BIAL Italia S.R.L.: 9001 - 2015
The American Heart Association distinguished the work of BIAL’s R&D team
Four researchers from BIAL’s Research and Development (R&D) area were recognized as a "2019 Paul Dudley White International Scholar" by the American Heart Association. At the American Heart Association Scientific Sessions 2019, an event held in Philadelphia. The award aims to recognize authors that contributed to the highest ranked accepted abstract from each country.
BIAL responds to the call and signs “Business Ambition for 1.5ºC” agreement
Signed by several business leaders, this initiative empowers companies worldwide, and BIAL has made the commitment. The initiative of the United Nations Global Compact, to which BIAL has been a signatory since 2004, establishes specific targets and emission reduction goals, in order to reach the net-zero emissions by 2050 and restrict the global warming in 1.5ºC by 2030. “The document encourages organizations to truly commit themselves to the preservation of the planet by requiring them to commit to concrete measures to reduce greenhouse gas emissions, critical to stop global warming. Achieving the transition to a low carbon economy and avoiding the atmosphere’s overheating are its main goals”, according to the Global Compact Network Portugal’s statement. Find out more at https://unglobalcompact.org/take-action/events/climate-action-summit-2019/business-ambition.
BIAL takes part of a recruitment event promoted by “Associação Salvador" - Porto, Portugal
The “Associação Salvador”, which promotes the inclusion of people with motor disabilities, organized this initiative which aimed to train and the job search for 40 candidates, in Porto BIAL joined this initiative promoted by Associação Salvador, which included a speed recruitment gathered 18 companies and several applicants, totaling over 210 interviews. At BIAL, we stand up for a more inclusive recruitment, insuring non-discrimination practices based on any personal characteristics, including social status, ethnicity, gender, age, religion, sexual orientation, marital status, political opinion, disability or incapacity. Learn more about our Code of Ethics and Conduct.
BIAL Foundation marks its 25th anniversary with an itinerant exhibition
To mark this occasion, the Foundation organizes the itinerant exhibition BIAL Foundation - 25 Years, which discloses the work developed on the study and scientific research of the human being during the last two decades.
BIAL has two new board members
José Almeida Bastos and Richard Pilnik integrate the Board of Directors of the biggest pharmaceutical company in Portugal José Almeida Bastos is now part of BIAL’s Executive Committee and responsible for both national and international commercial operations. Richard Pilnik has a 35 year career in the health sector, and is now non-executive member of BIAL’s Board of Directors. According to António Portela, CEO of BIAL, “it is an honor to have José Almeida Bastos and Richard Pilnik onboard. With their wide experience, they will endow the company with a more prepared structure to deal with upcoming challenges within the strategic lines we have defined, the research and development of new medicines, consolidated in an international scale. The Board of Directors of BIAL consists of 8 members: Luís Portela (Chairman), António Portela (CEO), Richard Pilnik (Non-Executive), Isabel Morgado, José Redondo, Miguel Portela, Patrício Soares da Silva and José Almeida Bastos.
“Prémio BIAL de Medicina Clínica 2018” distinguishes works about Gastric Cancer, Familial Hypercholesterolaemia and OCD
100.000 EUROS TO AWARD CLINICAL PRACTICE ATTRIBUTED BY THE BIAL FOUNDATION Mário Dinis Ribeiro is the winner of “Prémio BIAL de Medicina Clínica 2018” Mário Dinis Ribeiro – "Cancro Gástrico Em Portugal - Como reduzir a mortalidade por cancro gástrico em Portugal" - the winner of the "Prémio BIAL de Medicina Clínica 2018", with a "guide" to reduce gastric cancer deaths in Portugal, one of the deadliest in the country.
Prémio BIAL de Medicina Clínica 2018 distinguishes works about Gastric Cancer, Familial Hypercholesterolaemia and OCD
BIAL FOUNDATION AWARDS CLINICAL RESEARCH ON GASTRIC CANCER IN PORTUGAL WITH A €100,000 PRIZE Mário Dinis-Ribeiro wins the 2018 BIAL Award in Biomedicine Commendations for research in Familial Hypercholesterolemia and Obsessive Compulsive Disorder Mário Dinis-Ribeiro, Head of the Gastroenterology Service at the Portuguese Institute of Oncology of Porto and full professor at the College of Medicine of the University of Porto, won the 2018 BIAL Award in Biomedicine with the following study “Cancro Gástrico em Portugal - Como reduzir a mortalidade por cancro gástrico em Portugal” (Gastric Cancer in Portugal - How to reduce gastric cancer mortality in Portugal). The award-winning study followed, between 2005 and 2017, approx. 400 patients with malignant or premalignant gastric lesions. The approach used by Dinis-Ribeiro made it possible to define new guidelines for the detection and treatment of gastric cancer, one of the deadliest in Portugal, mainly due to late diagnosis and its high lethality. The performance of endoscopies enabled the removal of lesions in a minimally invasive manner, with a success rate (complication-free) of 80 to 85%. Among the patients included in the sample, the mortality rate was only 1% and never due to complications related to gastric cancer. Mário Dinis-Ribeiro highlights the role of endoscopy in the early detection of gastric cancer or cancer precursor lesions, which can replace surgery in many cases. Recommendations inherent to the main risk factors associated with gastric cancer are also explained in this paper: Helicobacter pylori infection and wrong dietary habits, as well as the intake of high amounts of salt and tobacco smoking.Mário Dinis-Ribeiro explains, “The results allow us to draw two types of conclusions and approaches to prevent and treat gastric cancer. First, at the prevention level, it is very important to alert the population to risk factors such as tobacco smoking and salt intake. Secondly, if we want to reduce the prevalence of gastric cancer, we must focus on the early treatment of lesions through upper endoscopy and prevent them from evolving.” The President of the European Society of Gastrointestinal Endoscopy and President of the Portuguese Society of Digestive Endoscopy highlights “The recommendation for gastric cancer screening must be a consideration of foremost importance, and according to the cost-effective ratio analysis, we advise patients to undergo an endoscopy procedure, simultaneously with colonoscopy. When the patient is screened for colorectal cancer, they should undergo endoscopy and thus be also screened for gastric cancer”. Currently, the only recommended screening for the digestive tract is colorectal cancer from the age of 50. Mário Dinis-Ribeiro concludes with a call to “The role of healthcare decision makers in considering gastric adenocarcinoma in the health agenda of Portugal”.
#SpreadingtheLight – International Epilepsy Day
BIAL MARKS THE DAY AND SPREADS THE LIGHT ON THE DISEASE The 11th February is the International Epilepsy Day and at BIAL we will dedicate the week to the disease and to the people who suffer from it, as it is the most common serious neurological condition, affecting around 50 million people worldwide.
BIAL takes responsibility for its website contents. By clicking “continue” below, you will be taken to an external website, beyond our responsibility.